Exact Sciences Corp (EXAS.OQ)
Tue, Mar 20 2018
* MARK STENHOUSE TO JOIN EXACT SCIENCES AS PRESIDENT, COLOGUARD
* ANTICIPATES COMPLETED COLOGUARD TEST VOLUME OF 900,000-920,000 TESTS DURING 2018.
BRIEF-Exact Sciences announces upsize, pricing of $600 mln of 1 pct convertible senior notes due 2025
* EXACT SCIENCES ANNOUNCES UPSIZE AND PRICING OF $600 MILLION OF 1.0% CONVERTIBLE SENIOR NOTES DUE 2025
* EXACT SCIENCES ANNOUNCES OFFERING OF $500 MILLION CONVERTIBLE SENIOR NOTES DUE 2025 Source text for Eikon: Further company coverage:
BRIEF-Exact Sciences Says "Comfortable" With Current 2018 Consensus Revenue Estimate Of Around $417 Mln
* EXACT SCIENCES CORP SAYS "COMFORTABLE" WITH CURRENT 2018 CONSENSUS REVENUE ESTIMATE OF AROUND $417 MILLION Source text for Eikon: Further company coverage:
BRIEF-Exact Sciences Says On Dec. 15, Co, Unit Entered Loan, Security Agreement For 24-Month Secured Revolving Credit Facility For Up To $15.0 Mln
* EXACT SCIENCES - ON DEC. 15, CO, UNIT ENTERED LOAN, SECURITY AGREEMENT FOR 24-MONTH SECURED REVOLVING CREDIT FACILITY FOR UP TO $15.0 MILLION - SEC FILING
* Exact Sciences Corp qtrly loss per share $0.23; qtrly revenue $72.6 million, up 158 percent
Exact Sciences Corp reported quarterly revenue that blew past analysts' estimates as demand for the company's sole diagnostic test, Cologuard, more than doubled.
Oct 30 Exact Sciences Corp reported quarterly revenue that blew past analysts' estimates as demand for the company's sole diagnostic test, Cologuard, more than doubled.
- Waiting For The Next Overreaction With Exact Sciences
- EXACT Sciences (EXAS) Presents At Barclays Global Healthcare Conference 2018 - Slideshow
- Steel Tariff Worries Are Overblown - Cramer's Mad Money (3/1/18)
- EXACT Sciences (EXAS) Q4 2017 Results - Earnings Call Transcript
- EXACT Sciences Corporation 2017 Q4 - Results - Earnings Call Slides
- Earnings Preview: Exact Sciences